Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Hepatocellular carcinoma: are we making progress?

Andrew X Zhu1

  • 1Massachusetts General Hospital, Dana-Farber/Partners Cancer Care, Harvard Medical School, Boston, Massachusetts, USA. azhu@partners.org

Cancer Investigation
|August 7, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Outcomes of radiotherapy of hepatocellular carcinoma: a retrospective analysis.

Radiation oncology (London, England)·2026
Same author

Uncovering the genetic landscape of cholangiocarcinoma and its subtypes via GWAS and integrative analyses.

Hepatology (Baltimore, Md.)·2026
Same author

Molecular subtypes of hepatocellular carcinoma linked to liver cell lineages and clinical outcomes of combination immunotherapy.

Cell reports. Medicine·2025
Same author

Targeting tumor-intrinsic BCL9 reverses immunotherapy resistance by eliciting macrophage-mediated phagocytosis and antigen presentation.

Nature communications·2025
Same author

Stereotactic Body Radiotherapy vs Sorafenib Alone in Hepatocellular Carcinoma: The NRG Oncology/RTOG 1112 Phase 3 Randomized Clinical Trial.

JAMA oncology·2024
Same author

Tislelizumab versus Sorafenib in First-Line Treatment of Unresectable Hepatocellular Carcinoma: Impact on Health-Related Quality of Life in RATIONALE-301 Study.

Liver cancer·2024

Hepatocellular carcinoma (HCC) remains a prevalent cancer with poor outcomes. Prevention strategies, including vaccines and interferon therapy for hepatitis, are crucial for managing this aggressive malignancy.

Area of Science:

  • Hepatocellular carcinoma (HCC) research
  • Oncology
  • Gastroenterology

Background:

  • Hepatocellular carcinoma (HCC) is a prevalent malignancy with increasing incidence globally and in the United States.
  • Despite available treatments, the prognosis for HCC remains poor, with limited curative options.
  • Current systemic chemotherapy for HCC has shown disappointing results.

Purpose of the Study:

  • To review the current landscape of hepatocellular carcinoma (HCC) management.
  • To highlight the importance of prevention strategies for HCC.
  • To discuss the potential of novel systemic therapies and localized treatments.

Main Methods:

  • Review of existing literature on hepatocellular carcinoma (HCC) treatment and prevention.
  • Analysis of current therapeutic approaches, including surgical resection, liver transplantation, and localized treatments.

Related Experiment Videos

  • Evaluation of systemic therapies, tumor biology, and drug development in HCC.

    • Main Results:

    • Surgical resection and liver transplantation are the only potentially curative treatments for HCC.
    • Localized treatment approaches remain important in HCC management.
    • Advancements in understanding HCC tumor biology may lead to more efficacious systemic agents.

    Conclusions:

    • Prevention of hepatocellular carcinoma (HCC) is a critical strategy due to poor treatment outcomes.
    • Vaccine programs for Hepatitis B (HBV) and Hepatitis C (HCV) are ongoing.
    • Interferon therapy shows promise in reducing HCC risk in patients with hepatitis, particularly HCV.